Aaron Ring, MD, PhD
Co-Founder

Dr. Ring is a recognized leader in the field of protein engineering and in its use for targeting novel pathways of the immune system. He was a primary inventor of the core technologies of Ab Initio Biotherapeutics. Additionally, he invented several promising immunotherapeutic agents while at Stanford, most notably, high-affinity SIRPα variants, which represent another potentially transformative advance in cancer immunotherapy. Currently, he is the Robert T. McCluskey Yale Scholar and Assistant Professor of Immunobiology at the Yale School of Medicine. Prior to his training at Stanford, Dr. Ring received concurrent B.S. and M.S. degrees in Molecular Biophysics and Biochemistry at Yale University, where he was awarded the Paul Sigler Memorial Prize. He has additionally been named a Beckman Scholar and a Goldwater Scholar, and was awarded with a Ruth L. Kirschstein National Research Service Award in recognition of his work. He was selected as a member of the 2016 Forbes 30 under 30 list in Healthcare.